Trials / Recruiting
RecruitingNCT06780150
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 842 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocrelizumab | Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling. |
Timeline
- Start date
- 2024-09-26
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2025-01-17
- Last updated
- 2026-03-30
Locations
78 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT06780150. Inclusion in this directory is not an endorsement.